PCOS and Hashimoto’s: The Antibody Test No One Ran

If you have PCOS (polycystic ovary syndrome, a hormonal condition that affects ovulation, androgen levels, and metabolic function) and you have been told your thyroid is “fine” because your TSH (thyroid-stimulating hormone, the standard blood marker your doctor orders to screen for thyroid problems) came back normal, I want to sit with that for a moment, because “normal TSH” and “no thyroid problem” are not the same thing, and in cases I’ve reviewed, this distinction gets missed constantly.

Here is what I mean. PCOS roughly doubles the odds of autoimmune thyroiditis, about 23% versus 6%, per a 2022 meta-analysis by Hu and colleagues covering 7,857 women across 20 studies and 13 countries. That means roughly one in four women with PCOS may also carry Hashimoto’s thyroiditis (an autoimmune condition where the immune system produces antibodies that attack the thyroid gland). And a normal TSH does not rule it out, because in the early stage of Hashimoto’s, the thyroid is still compensating. The antibodies are already there. The TSH has not budged yet.

What follows is not a prescription. It is an explanation of what the research shows, what the screening gap looks like in practice, and exactly what to ask your doctor at your next appointment. I will also be honest about where the evidence runs out, because that honesty is the thing most wellness content on this topic skips entirely.

This post covers: how PCOS and Hashimoto’s overlap, why a normal TSH is not the whole picture, what the research actually shows about supplements like selenium and vitamin D, and the exact lab panel and conversation script to bring to your next appointment.

Can You Have PCOS and Hashimoto’s at the Same Time?

Yes, and it happens more often than most women are told. The short answer: having PCOS roughly doubles your odds of also having Hashimoto’s thyroiditis compared to women without PCOS, based on four independent meta-analyses that agree on both the direction and the approximate magnitude of the risk.

The research on this has been building for over a decade. The clearest numbers come from Hu et al. 2022, a meta-analysis of 7,857 women, which found Hashimoto’s prevalence in PCOS ran roughly 22.8% versus 5.7% in women without PCOS. A 2024 meta-analysis by Bahreiny and colleagues, covering 3,657 participants, put the odds ratio for autoimmune thyroid disease in PCOS at 2.38 (meaning women with PCOS had roughly 2.4 times the odds of autoimmune thyroiditis compared to controls). A 2025 meta-analysis by Kwiatkowski and colleagues, the largest to date at 6,045 PCOS women versus 4,527 controls, found anti-TPO antibodies (proteins your immune system makes that attack your own thyroid) were twice as common in PCOS, odds ratio 2.03, even when TSH reads normal.

If you have been living with both and no one connected the dots, you are not imagining things. The system genuinely is not set up to catch this overlap in one appointment.

What this means for the woman trying to make sense of two separate diagnoses: they are not separate problems requiring two separate specialists who never talk to each other. They share metabolic and immune ground, and understanding that changes what you ask for.

Why Does PCOS Increase Hashimoto’s Risk?

The honest answer is that researchers have candidates but no single confirmed cause, and the field has not converged.

Before I explain what’s proposed, let me define the key terms. Hashimoto’s thyroiditis (also called autoimmune thyroiditis, or Hashimoto’s disease) is a condition where the immune system produces antibodies against the thyroid gland. Over time, this immune attack can slow thyroid function. Euthyroid Hashimoto’s means antibodies are present but thyroid hormone levels are still in the normal range, which is why TSH can look fine even when the autoimmune process is already underway. Anti-TPO antibodies (anti-thyroid peroxidase) and anti-TG antibodies (anti-thyroglobulin) are the two markers that detect this immune activity.

The proposed mechanisms behind the PCOS-Hashimoto’s link involve three overlapping threads, drawing from a narrative review by Kowalczyk et al. 2017.

Shared genetics

Certain gene variants are associated with both conditions, particularly in genes regulating TGF-beta (a molecule involved in immune balance) and estrogen metabolism. These genetic overlaps do not mean PCOS causes Hashimoto’s or the reverse. They suggest a shared biological terrain that predisposes some women to both.

Hormonal immune disruption

PCOS is defined partly by irregular ovulation, which means the normal monthly cycle of estrogen and progesterone is disrupted. This matters for immune regulation because progesterone has a calming effect on certain immune responses. A chronically elevated ratio of estrogen to progesterone may tilt the immune system toward autoimmunity. This is a plausible mechanism, not a proven causal chain.

Vitamin D insufficiency

Vitamin D (a fat-soluble hormone-like nutrient involved in immune regulation) is commonly low in women with both PCOS and Hashimoto’s. Whether vitamin D deficiency contributes to both conditions, is a consequence of them, or is a third factor unrelated to either is still being studied. A 2014 review by Muscogiuri et al. concluded observational data supports a role while randomized controlled trials are still needed. That gap in the evidence has not been fully closed since.

What I want you to understand is that mechanism is a teaching tool here, not a treatment justification. “These conditions share a biological root” does not mean “fix the root and both go away.” The research has not shown that. More on this below.

The proposed mechanisms are plausible and worth understanding, but none has been shown to translate into a clinical intervention that resolves one condition by treating the other.

What Does “Normal TSH” Actually Mean When You Have PCOS?

If your TSH came back in the normal range (roughly 0.4 to 4.0 mIU/L, though reference ranges vary by lab), your doctor told you your thyroid is fine. And here is where I have to complicate that for you.

TSH is a pituitary signal, not a direct measure of thyroid tissue health. It tells you how hard the pituitary gland is working to stimulate the thyroid. In early Hashimoto’s, the thyroid gland is still producing enough hormone to keep TSH within range, even while the immune attack is already underway. The antibodies are measurable. The TSH has not shifted yet. This stage is called euthyroid (meaning normal thyroid hormone levels) Hashimoto’s, and it is exactly the window where antibody testing adds information that TSH alone cannot.

I’ve seen women arrive with years of fatigue, weight that would not move, and a brain that felt like it was working through wet sand, all while being told their TSH was normal. The anti-TPO had never been run.

Anti-TPO antibodies (anti-thyroid peroxidase antibodies) are the immune marker most commonly elevated in Hashimoto’s, and they can be positive before TSH changes. Anti-TG antibodies (anti-thyroglobulin antibodies) add sensitivity. Some women with Hashimoto’s test positive on anti-TG but not anti-TPO, so checking both catches more cases than either alone.

Free T4 (free thyroxine, the main thyroid hormone circulating in the blood, available for use by tissues) and free T3 (free triiodothyronine, the active form of thyroid hormone) round out the picture when symptoms suggest more is going on than TSH alone reflects. Subclinical hypothyroidism (a condition where TSH is mildly elevated but thyroid hormone levels are still normal, often without obvious symptoms) sits between normal thyroid function and overt hypothyroidism, and it is another reason why checking multiple markers matters more than relying on one number.

Now, here is the honest caveat, the one most content on this topic omits. The 2025 Kwiatkowski meta-analysis, which is the most rigorous of the four because it specifically matched PCOS and control women for both BMI and baseline TSH, found something important: when the groups were matched for body weight and baseline thyroid status, the prevalence difference in antibody positivity was no longer statistically significant. The antibody levels stayed elevated, but the prevalence gap shrank. This means part of what looks like a PCOS-specific thyroid risk may actually be explained by higher average body weight and TSH variability in PCOS women, not by PCOS biology alone.

Anti-TPO antibodies are twice as common in PCOS, odds ratio 2.03, even when TSH reads normal, per Kwiatkowski 2025. But the association is real, not absolute, and partly explained by BMI and baseline thyroid status.

What this does not mean is that the antibody screening is pointless. It means the case for screening is strong and evidence-grounded, not the ironclad “PCOS definitely means thyroid problems” that some wellness content implies. You deserve the more accurate version.

What the Guidelines Already Say About Thyroid Testing in PCOS

This is not fringe naturopathic medicine. Mainstream guidelines already say thyroid testing is mandatory before settling a PCOS diagnosis.

The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, endorsed by 39 organizations across 71 countries and published by Teede and colleagues in the Journal of Clinical Endocrinology and Metabolism, requires that thyroid disease be excluded before diagnosing PCOS. The Endocrine Society PCOS Clinical Practice Guideline lists TSH testing alongside prolactin as part of the standard workup to rule out conditions that can mimic PCOS symptoms.

The logic is straightforward: hypothyroidism (underactive thyroid, a condition where the thyroid does not produce enough hormone) can cause irregular periods, weight gain, and fatigue. All of these overlap with PCOS symptoms. A doctor who diagnoses PCOS without first excluding thyroid disease may be labeling a thyroid problem as a hormonal one.

Where the guidelines stop short is on thyroid antibody testing. Neither the 2023 international guideline nor the Endocrine Society explicitly mandates running anti-TPO and anti-TG panels in every PCOS patient. TSH testing is the hard requirement. Antibody screening sits in the space of “supported by meta-analytic association, not yet a universal mandated standard.” That gap is where the clinical reasoning I want to walk you through lives.

The Overlap Symptom Trap: Why Both Conditions Hide Each Other

A patient had been diagnosed with PCOS at 29. By 38, she was still cycling irregularly, had gained weight she could not explain, and described her brain as “permanently offline.” Every year, her TSH came back at around 2.1. “Your thyroid is fine,” she was told. In cases I’ve reviewed with this profile, the next question I would always ask is: did anyone check the antibodies?

The symptom overlap between PCOS and Hashimoto’s is where the diagnostic confusion lives. Both conditions can produce fatigue that goes beyond tired. Both are associated with weight that resists normal interventions. Both can slow cognition. Both are associated with hair loss. Both can affect menstrual regularity and fertility. When one condition is labeled, the other gets attributed to it, and the workup stops there.

This matters especially as women move into the 41-to-45 age range, where perimenopause (the hormonal transition that precedes menopause, often beginning in the early to mid-40s and characterized by estrogen fluctuation, cycle irregularity, and symptoms including sleep disruption, brain fog, and mood changes) starts overlapping with both PCOS and thyroid symptoms. Hot flashes, weight changes, and fatigue get attributed to “just perimenopause” while an undiagnosed Hashimoto’s or worsening thyroid function continues unchecked.

For the 30-to-35 cohort, the most common version of this I’ve seen discussed is the fertility angle. Both PCOS and Hashimoto’s independently affect ovulation and pregnancy outcomes. A woman trying to conceive who has been worked up for PCOS but not for thyroid antibodies has an incomplete picture. And in that context, the incomplete picture has real stakes.

The symptom overlap between PCOS and Hashimoto’s is the diagnostic trap, and the solution is not guessing which label fits better. It is running the complete picture.

What About Selenium and Vitamin D? Honest Evidence Only.

Selenium is the supplement most discussed in this space. The Cochrane systematic review, which pooled four randomized controlled trials covering 463 participants, found that selenomethionine at 200 mcg daily did reduce anti-TPO antibody levels compared to placebo, with statistical significance. That sounds like a win. Here is the part that gets left out: the Cochrane reviewers concluded the evidence was incomplete and unreliable for clinical decision-making. The antibody changes were of unclear clinical relevance. One well-being finding came from a trial with high risk of bias. Antibody levels are a surrogate marker, not the outcome that matters. The outcomes that matter are thyroid function, symptoms, and in women with PCOS, fertility and metabolic markers. None of those have been shown to improve with selenium in this population.

Selenium at 200 mcg lowers thyroid antibodies, but Cochrane’s four trials found no proven symptom benefit. Antibody reduction and clinical improvement are not the same thing, and in women with PCOS who are also insulin-resistant, there is an additional reason for caution: higher selenium intake is associated with worse glycemic control and a possible increased risk of type 2 diabetes. The NIH Office of Dietary Supplements sets the tolerable upper intake level at 400 mcg per day, with selenosis (selenium toxicity presenting with hair loss, brittle nails, and GI symptoms) a real risk at higher amounts. The window between “possibly useful” and “potentially problematic” is narrow.

Vitamin D follows a similar pattern. Observational studies consistently show lower vitamin D levels in women with both PCOS and Hashimoto’s. A review by Muscogiuri et al. 2014 concluded the observational data is supportive while randomized trials are still needed. Those trials still have not been run in a combined overlap population. Low vitamin D is worth checking and correcting if deficient, but “vitamin D is low in this population” is not the same as “vitamin D supplementation reverses Hashimoto’s.”

The bigger issue is this: no overlap-specific randomized controlled trials have been run yet. The intervention evidence in this population does not exist. Every supplement recommendation you read for women who have both PCOS and Hashimoto’s is borrowed from single-condition trials that did not enroll the overlap phenotype as the defined population. That is not nothing, but it is not proof of benefit for the woman who has both. Calling it proven would be dishonest.

What I share with people who ask me about this: the mechanistic case for selenium and vitamin D is plausible. The clinical evidence for patient-relevant outcomes is not there yet. If you are working with a clinician who wants to assess your vitamin D and address a documented deficiency, that is reasonable. Treating selenium as a cure for Hashimoto’s, especially without knowing your baseline selenium status and while managing insulin resistance, is not something the evidence supports.

What I’d Do This Week

This section is the practical takeaway. It is not a treatment plan, it is a conversation to have with your healthcare provider at your next appointment.

SAVE CARD: The PCOS Thyroid Panel (What to Ask For, and What Each Test Tells You)

If you have PCOS, this is the panel that is often skipped. Bring it to your next labs.

TSH (thyroid-stimulating hormone) The screening standard, already required to diagnose PCOS. A normal TSH (roughly 0.4 to 4.0 mIU/L) does not rule out Hashimoto’s. It is the start, not the whole story.

Anti-TPO antibodies (anti-thyroid peroxidase antibodies) The test most often left off. These can be elevated while TSH still reads normal. A positive anti-TPO with a normal TSH points to early (euthyroid) Hashimoto’s: a reason to monitor, not automatically to medicate.

Anti-TG antibodies (anti-thyroglobulin antibodies) Adds sensitivity. Some Hashimoto’s is anti-TG positive and anti-TPO negative, so checking both catches more.

Free T4 (free thyroxine) Measures the available thyroid hormone. Paired with TSH, it stages how the thyroid is actually functioning.

Free T3 (free triiodothyronine) Optional. Useful when symptoms outpace what TSH and free T4 show. Reverse T3 is popular online but not routinely needed for initial screening.

What to Say (The 3-Line Script)

1.        “I have PCOS. Can we add thyroid antibodies, anti-TPO and anti-TG, to my labs, not just TSH?”

2.        “If my antibodies are positive but my TSH is normal, what is our monitoring plan?”

3.        “Given my PCOS, how often should we recheck this over time?”

Caveat row (read this before you act on it): A positive antibody with a normal TSH usually means watchful monitoring, not medication. Screening adds information; it does not mean you need treatment. If you are pregnant or trying to conceive, the calculus changes and thyroid decisions belong with your physician.

The “But Actually” on Treating One to Fix the Other

Here is where I want to push back on something that circulates widely in the wellness space: the idea that treating Hashimoto’s will resolve PCOS, or that addressing PCOS will fix the thyroid. The evidence does not support either direction.

No study has demonstrated that treating thyroid disease resolves PCOS. They are distinct conditions that co-occur. Fixing the thyroid may relieve some symptoms that overlap (fatigue, weight difficulty, cycle irregularity), but PCOS is a hormonal condition with its own androgen and insulin-resistance drivers that do not disappear because thyroid function improves. The reverse is also true. Managing PCOS does not resolve autoimmune thyroid disease. The antibodies do not go away because you lower insulin or restore ovulation.

The “but actually” position: pharma versus naturopathy is not the choice here. The choice is thorough versus incomplete. A woman who has been told she has PCOS and whose TSH is normal has not been told the whole picture. She deserves the antibody test. She also deserves honesty that the antibody test adds information, not a cure. If her antibodies are positive and her TSH is still normal, watchful monitoring is appropriate. If her TSH climbs into subclinical hypothyroidism, that conversation belongs with a physician who can stage it correctly. If she is planning a pregnancy, thyroid management in that context is physician-directed without exception, because untreated hypothyroidism in pregnancy carries real risks to fetal neurological development.

Levothyroxine (a prescription synthetic thyroid hormone medication used to treat hypothyroidism) remains the standard pharmaceutical treatment when thyroid replacement is indicated. Desiccated thyroid products (natural animal-derived thyroid preparations sometimes marketed as an alternative to levothyroxine) are not interchangeable with prescribed medication and should not be self-started. These are physician-managed decisions, and the education role here is to get you to that conversation fully informed, not to replace it.

The association between PCOS and Hashimoto’s is real, well-documented, and actionable at the screening level. The evidence that treating one resolves the other is not there. You deserve both of those truths.

Conclusion: What “Fully Worked Up” Actually Means

PCOS roughly doubles the odds of autoimmune thyroiditis, about 23% versus 6%, per Hu 2022 meta-analysis. The evidence is strong. The clinical implication is clear: a normal TSH alone does not complete the thyroid picture for a woman with PCOS.

What I want to leave you with is not a supplement to buy or a protocol to start. It is a question to bring to your next appointment and the knowledge that asking it is grounded in four independent meta-analyses and international clinical guidelines, not in wellness influencer content.

The system as it is currently structured gives you a PCOS label from one doctor and a “normal TSH” from another, and often no one adds anti-TPO. That is the gap. Naming it and knowing the exact words to close it is what this post is for.

If you have been told you are fine but you do not feel fine, you may not be fully worked up yet. That is not a reflection on you. It is a gap in how two common conditions get managed in two separate offices that rarely talk.

What is the symptom that has kept you guessing even after you got a diagnosis? I’d genuinely like to know, because those are the questions I’m here to answer.

This content is for educational purposes only and is not medical advice. Please consult with your healthcare provider for individual recommendations.

Frequently Asked Questions

1) Can you have both PCOS and Hashimoto’s at the same time?

Yes. Four meta-analyses consistently show women with PCOS carry roughly twice the odds of autoimmune thyroiditis compared to women without PCOS. Hashimoto’s prevalence in PCOS ranges from approximately 22 to 27% versus 6 to 8% in controls. Having both is common enough that the overlap warrants specific screening, not a single-diagnosis assumption.

2) Does PCOS cause Hashimoto’s, or does Hashimoto’s cause PCOS?

Neither has been proven to cause the other. The relationship is observational: both conditions occur together more often than chance. Shared genetic variants, hormonal immune disruption, and vitamin D insufficiency are candidate mechanisms, but the direction of causation is not established. “Associated with” is the honest description, not “causes.”

3) What is the full thyroid panel I should ask for if I have PCOS?

Ask for TSH (already standard in PCOS workup), anti-TPO antibodies, anti-TG antibodies, and free T4. Add free T3 if symptoms seem disproportionate to what TSH and free T4 show. A normal TSH does not rule out early Hashimoto’s; the antibody tests are what catch it in the euthyroid stage.

4) Will treating my thyroid fix my PCOS weight gain?

Probably not in full. If you have untreated hypothyroidism alongside PCOS, treating it may improve some thyroid-related metabolic drag. But PCOS has its own androgen and insulin-resistance drivers that do not resolve with thyroid treatment. Expect partial improvement at best, and work with a clinician on both conditions as distinct problems.

5) Should I take selenium or vitamin D for Hashimoto’s if I also have PCOS?

The evidence is limited. Selenium at 200 mcg lowers thyroid antibodies in trials, but Cochrane reviewers found the clinical benefit unproven, and women with insulin resistance (common in PCOS) face an additional reason for caution given selenium’s association with glycemic changes. Vitamin D insufficiency is common and worth correcting if deficient, but supplementation has not been shown to reverse Hashimoto’s. Neither should be self-started as a treatment without lab testing and clinician guidance.

6) What if my TSH is normal, but I still feel terrible?

A normal TSH is the start of the thyroid picture, not the end. In early Hashimoto’s, TSH can remain in range while anti-TPO antibodies are already elevated and the autoimmune process is underway. Asking your provider to add thyroid antibody testing (anti-TPO and anti-TG) to your labs is a reasonable, evidence-grounded next step, especially if you also have PCOS.

References

1. Bahreiny, S. S., Ahangarpour, A., Amraei, M., et al. (2024). Autoimmune thyroid disorders and polycystic ovary syndrome: Tracing links through systematic review and meta-analysis. Journal of Reproductive Immunology, 163, 104215. https://doi.org/10.1016/j.jri.2024.104215

2. Kwiatkowski, J., Akpang, N., Zaborowska, L., & Ludwin, A. (2025). Prevalence and levels of thyroid autoantibodies in polycystic ovary syndrome: Impact of TSH- and BMI-matched comparisons. International Journal of Molecular Sciences, 26(15), 7525. https://doi.org/10.3390/ijms26157525

3. Hu, X., Chen, Y., Shen, Y., et al. (2022). Correlation between Hashimoto’s thyroiditis and polycystic ovary syndrome: A systematic review and meta-analysis. Frontiers in Endocrinology, 13, 1025267. https://doi.org/10.3389/fendo.2022.1025267

4. Du, D., & Li, X. (2013). The relationship between thyroiditis and polycystic ovary syndrome: A meta-analysis. International Journal of Clinical and Experimental Medicine, 6(10), 880-889.

5. Kowalczyk, K., Franik, G., Kowalczyk, D., et al. (2017). Thyroid disorders in polycystic ovary syndrome. European Review for Medical and Pharmacological Sciences, 21(2), 346-360.

6. Muscogiuri, G., Tirabassi, G., Bizzaro, G., et al. (2014). Vitamin D and thyroid disease: To D or not to D? European Journal of Clinical Nutrition, 69(3), 291-296. https://doi.org/10.1038/ejcn.2014.265

7. van Zuuren, E. J., Albusta, A. Y., Fedorowicz, Z., et al. (2014). Selenium supplementation for Hashimoto’s thyroiditis: Summary of a Cochrane systematic review. European Thyroid Journal, 3(1), 25-31.

8. Teede, H. J., et al. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 108(10), 2447-2469.

9. NIH Office of Dietary Supplements. (n.d.). Selenium: Health professional fact sheet. https://ods.od.nih.gov/factsheets/Selenium-HealthProfessional/

10. Marcinowska-Suchowierska, E., et al. (2018). Vitamin D toxicity: A clinical perspective. Frontiers in Endocrinology, 9, 550.